| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Bernard Coulie is President and CEO at PLRX. Bernard Coulie's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $435K at current prices.
Our model assigns Bernard Coulie a strong insider score of 80/100, based on 28 past trades. Over a 12-month horizon, all 27 of those trades were profitable, with an average 12-month return of +43.1%.
The PLRX filings lean toward selling, a net 650,926 shares.
Bernard Coulie has 34 Form 4 filings on record from June 2020 to June 2026, across 2 companies: Director at Septerna (SEPN), 2025–2026; President and CEO at Pliant Therapeutics (PLRX), 2020–2026.
The 103 reported transactions were 51 open-market sales, 21 option exercises, 16 option or other derivative awards and 7 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 22 sales worth about $13.6M.
The largest open-market sale was 60,000 shares of PLRX at an average $33.12 on January 25, 2023, about $2.0M. Twelve months later PLRX was down 50%.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 89,375 | $1.28 | $114,400.00 | -15.0% | +0.8% | - | |
| Jan 17, 2025 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 52,419 | $11.20 | $587,150.46 | -10.9% | -87.0% | -88.5% | |
| Jul 10, 2024 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 38,710 | $11.56 | $447,487.60 | -7.4% | +1.4% | -87.4% | |
| Jan 17, 2024 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 25,721 | $17.23 | $443,172.83 | -7.5% | -25.7% | -35.0% | |
| Jul 17, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 70,150 | $18.01 | $1,263,338.37 | -17.0% | -13.7% | -24.3% | |
| Mar 30, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sell10b5-1 | 35,339 | $26.52 | $937,222.09 | -11.4% | -28.3% | -43.9% | |
| Feb 3, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sale+OE | 30,000 | $33.91 | $1,017,429.85 | -11.1% | -32.1% | -47.9% | |
| Feb 1, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sale+OE | 45,000 | $34.48 | $1,551,637.07 | -15.8% | -32.4% | -46.5% | |
| Jan 27, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sale+OE | 55,000 | $35.32 | $1,942,335.71 | -11.8% | -19.7% | -50.8% | |
| Jan 25, 2023 | PLRX Pliant Therapeutics, Inc. | President and CEO | Sale+OE | 60,000 | $33.12 | $1,987,473.18 | -39.0% | -12.6% | -50.3% |